Knocking on fxr´s door: The "hammerhead"-structure series of fxr agonists – amphiphilic isoxazoles with potent in vitro and in vivo activities

Current Topics in Medicinal Chemistry

Volumn 14, Issue 19, 2014, Pages 2143-2158

  Gege, Christian ^a   Kinzel, Olaf ^a   Steeneck, Christoph ^a   Schulz, Andreas ^a   Kremoser, Claus ^a  

^a PHENEX PHARMACEUTICALS AG   (Germany)

Author keywords

Bile acid receptor; Farnesoid X receptor; FXR agonist; GW4064; Isoxazole; NAFLD; NASH; Px 102; PX20606

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2, 6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY] PHENYL] VINYL] BENZOIC ACID; AMPHOPHILE; FARNESOID X RECEPTOR; ISOXAZOLE DERIVATIVE; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

AGONIST; ARTICLE; CHRONOLOGY; EC50; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; PATENT; PX 102; PX 104; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; AGONISTS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY;

ANIMALS; HUMANS; IN VITRO TECHNIQUES; ISOXAZOLES; MODELS, MOLECULAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925881991     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141112094430     Document Type: Article

References (71)

1. Parks, D.J.; Blanchard, S.G.; Bledsoe, R.K.; Chandra, G.; Consler, T.G.; Kliewer, S.A.; Stimmel, J.B.; Willson, T.M.; Zavacki, A.M.; Moore, D.D.; Lehmann, J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science, 1999, 284, 1365–1368.
2. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a nuclear receptor for bile acids. Science, 1999, 284, 1362–1365.
3. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, R.M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 1995, 81, 687–693.
4. Higashiyama, H.; Kinoshita, M.; Asano, S. Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. Acta Histochem., 2008, 110, 86–93.
5. Bookout, A.L.; Jeong, Y.; Downes, M.; Yu, R.; Evans, R.M.; Mangelsdorf, D.J. Tissue-specific expression patterns of nuclear receptors. www.nursa.org/10.1621/datasets.02001 (Accessed July 9, 2014).
6. Kalaany, N.Y.; Mangelsdorf, D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol., 2006, 68, 159–191.
7. Calkin, A.C.; Tontonoz, P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol., 2012, 13, 213–224.
8. Inagaki, T.; Moschetta, A.; Lee, Y.K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R.T.; Shelton, J.M.; Richardson, J.A.; Repa, J.J.; Mangelsdorf, D.J.; Kliewer, S.A. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 3920–3925.
9. Gadaleta, R.M.; van Erpecum, K.J.; Oldenburg, B.; Willemsen, E.C.L.; Renooij, W.; Murzilli, S.; Klomp, L.W.J.; Siersema, P.D.; Schipper, M.E.I.; Danese, S.; Penna, G.; Laverny, G.; Adorini, L.; Moschetta, A.; van Mil, S.W.C. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut, 2011, 60, 463–472.
10. Chen, W.-D.; Wang, Y.-D.; Meng, Z.; Zhang, L.; Huang, W. Nuclear bile acid receptor FXR in the hepatic regeneration. Biochim. Biophys. Acta. 2011, 1812, 888–892.
11. Modica, S.; Gadaleta, R.M.; Moschetta, A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal. 2010, 8, e005.
12. Porez, G.; Prawitt, J.; Gross, B.; Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid. Res., 2012, 53, 1723–1737.
13. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P.R.; Morelli, A.; Parks, D.J.; Willson, T.M. 6- Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem., 2002, 45, 3569–3572.
14. Mudaliar, S.; Henry, R.R.; Sanyal, A.J.; Morrow, L.; Marschall, H.-U.; Kipnes, M.; Adorini, L.; Sciacca, C.I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology, 2013, 145, 574–582.
15. Kowdley, K.; Hirschfield, G.; Chapman, R.; Vincent, C.; Jones, D.; Pares, A.; Luketic, V.; Gordon, S.; Pencek, R.; Marmon, T.; Hooshmand-Rad, R. Long-term treatment of primary biliary cirrhosis with the FXR agonist obeticholic acid shows durable efficacy. J. Hepatol. 2014, 60, S192-S193;
16. Nevens, F., Andreone, P., Mazzella, G., Strasser, S., Bowlus, C., Invernizzi, P., Drenth, J., Pockros, P., Regula, J., Hansen, B., Hooshmand-Rad, R., Sheeron, S., Shapiro, D. The first primary biliary cirrhosis (PBC) phase 3 trial in two decades – an international study of the FXR agonist obeticholic acid in PBC patients. J. Hepatol., 2014, 60, S525–S526.
17. Silveira, M.G.; Lindor, K.D. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin. Pharmacother., 2014, 15, 365–372.
18. Press Release Intercept Pharmaceuticals and NIDDK (http://ir.interceptpharma.com/releasedetail.cfm?releaseid=818119), see also: http://clinicaltrial.gov/ct2/show/NCT01265498 (Accessed July 9, 2014).
19. Maloney, P.R.; Parks, D.J.; Haffner, C.D.; Fivush, A.M.; Chandra, G.; Plunket, K.D.; Creech, K.L.; Moore, L.B.; Wilson, J.G.; Lewis, M.C.; Jones, S.A.; Willson, T.M. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem., 2000, 43, 2971–2974.
20. Akwabi-Ameyaw, A.; Bass, J.Y.; Caldwell, R.D.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Jones, S.A.; Kaldor, I.; Liu, Y.; Madauss, K.P.; Marr, H.B.; McFadyen, R.B.; Miller, A.B.; Navas, F.; Parks, D.J.; Spearing, P.K.; Todd, D.; Williams, S.P.; Wisely, G.B. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.Bioorg. Med. Chem. Lett., 2008, 18, 4339-4343.
21. Feng, S.; Yang, M.; Zhang, Z.; Wang, Z.; Hong, D.; Richter, H.; Benson, G.M.; Bleicher, K.; Grether, U.; Martin, R.E.; Plancher, J.- M.; Kuhn, B.; Rudolph, M.G.; Chen, L. Identification of an Noxide pyridine GW4064 analog as a potent FXR agonist. Bioorg. Med. Chem. Lett., 2009, 19, 2595–2598.
22. Bass, J.Y.; Caldwell, R.D.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Madauss, K.P.; Marr, H.B.; McFadyen, R.B.; Miller, A.B.; Parks, D.J.; Todd, D.; Williams, S.P.; Wisely, G.B. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064. Bioorg. Med. Chem. Lett., 2009, 19, 2969–2973.
23. Akwabi-Ameyaw, A.; Bass, J.Y.; Caldwell, R.D.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Madauss, K.P.; Marr, H.B.; McFadyen, R.B.; Miller, A.B.; Navas, F.; Parks, D.J.; Spearing, P.K.; Todd, D.; Williams, S.P.; Wisely, G.B. FXR agonist activity of conformationally constrained analogs of GW 4064. Bioorg. Med. Chem. Lett., 2009, 19, 4733–4739.
24. Abel, U.; Schlüter, T.; Schulz, A.; Hambruch, E.; Steeneck, C.; Hornberger, M.; Hoffmann, T.; Perovi-Ottstadt, S.; Kinzel, O.; Burnet, M.; Deuschle, U.; Kremoser, C. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg. Med. Chem. Lett., 2010, 20, 4911–4917.
25. Bass, J.Y.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Madauss, K.P.; Marr, H.B.; McFadyen, R.B.; Miller, A.B.; Mills, W.Y.; Navas, F.; Parks, D.J.; Smalley Jr, T.L.; Spearing, P.K.; Todd, D.; Williams, S.P.; Wisely, G.B. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg. Med. Chem. Lett., 2011, 21, 1206–1213.
26. Akwabi-Ameyaw, A.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Madauss, K.P.; Marr, H.B.; Miller, A.B.; Navas, F.; Parks, D.J.; Spearing, P.K.; Todd, D.; Williams, S.P.; Wisely, G.B. Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene. Bioorg. Med. Chem. Lett., 2011, 21, 6154–6160.
27. For former reviews see: (a) Crawley, M.L. Farnesoid X receptor modulators: a patent review. Expert Opin Ther. Pat. 2010, 20, 1047-1057;
28. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med. Chem., 2012, 4, 1015–1036.
29. Bell, M.G.; Doti, R.A.; Dowling, M.S.; Genin, M.J.; Lander, P.A.; Ma, T.; Mantlo, N.B.; Ochoada, J.M.; Stelzer, L.S.; Stites, R.E.; Warshawsky, A.M. Compounds and methods for modulating FXR. PCT Int. Appl. WO2007/140174, 2007 (Eli Lilly and Company).
30. Bell, M.G.; Doti, R.A.; Genin, M.J.; Lander, P.A.; Ma, T.; Manninen, P.R.; Ochoada, J.M.; Qu, F.; Stelzer, L.S.; Stites, R.E.; Warshawsky, A.M. FXR agonists. PCT Int. Appl., WO2007/140183, 2007 (Eli Lilly and Company).
31. Genin, M.J.; Agejas-Chicharro, F.J.; Bueno Melendo, A.B.; Manninen, P.R.; Warshawsky, A.M. Compounds and methods for modulating FXR. PCT Int. Appl., WO2009/012125, 2009 (Eli Lilly and Company).
32. Hambruch, E.; Miyazaki-Anzai, S.; Hahn, U.; Matysik, S.; Boettcher, A.; Perovi-Ottstadt, S.; Schlüter, T.; Kinzel, O.; Krol, H.D.; Deuschle, U.; Burnet, M.; Levi, M.; Schmitz, G.; Miyazaki, M.; Kremoser, C. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (–/–) mice. J. Pharmacol. Exp. Ther., 2012, 343, 556–567.
33. Sirvent, A.; Claudel, T.; Martin, G.; Brozek, J.; Kosykh, V.; Darteil, R.; Hum, D.W.; Fruchart, J.-C.; Staels, B. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett., 2004, 566, 173–177.
34. Liu, Y.; Binz, J.; Numerick, M.J.; Dennis, S.; Luo, G.; Desai, B.; MacKenzie, K.I.; Mansfield, T.A.; Kliewer, S.A.; Goodwin, B.; Jones, S.A. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest., 2003, 112, 1678–1687.
35. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, T.H.; Grefhorst, A.; Abdelkarim, M.; Caron, S.; Torpier, G.; Fruchart, J.- C.; Gonzalez, F.J.; Kuipers, F.; Staels, B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem., 2006, 281, 11039–11049.
36. Zhang, Y.; Lee, F.Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F.J.; Willson, T.M.; Edwards, P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 1006–1011.
37. Jung, D.; Inagaki, T.; Gerard, R.D.; Dawson, P.A.; Kliewer, S.A.; Mangelsdorf, D.J.; Moschetta, A. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid. Res., 2007, 48, 2693–2700.
38. Houten, S.M.; Volle, D.H.; Cummins, C.L.; Mangelsdorf, D.J.; Auwerx, J. In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol. Endocrinol., 2007, 21, 1312–1323.
39. Ma, Y.; Huang, Y.; Yan, L.; Gao, M.; Liu, D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm. Res., 2013, 30, 1447–1457.
40. Hoekstra, M.; van der Sluis, R.J.; Li, Z.; Oosterveer, M.H.; Groen, A.K.; van Berkel, T.J.C. FXR agonist GW4064 increases plasma glucocorticoid levels in C57BL/6 mice. Mol. Cell. Endocrinol., 2012, 362, 69–75.
41. Deuschle, U.; Schüler, J.; Schulz, A.; Schlüter, T.; Kinzel, O.; Abel, U.; Kremoser, C. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One, 2012, 7, e43044.
42. http://clinicaltrials.gov/ct2/show/NCT01999101 (Accessed July 9, 2014).
43. Blanchard, S.G.; Kliewer, A.; Lehmann, J.; Parks, D.J.; Stimmel, J.B.; Willson, T.M. Assays for ligands for nuclear receptors. PCT Int. Appl., WO2000/037077, 2000 (Glaxo Group Ltd.).
44. Sugihara, K.; Kitamura, S; Sanoh, S.; Ohta, S.; Fujimoto, N.; Maruyama, S.; Ito, A. Metabolic activation of the proestrogens transstilbene and trans-stilbene oxide by rat liver microsomes. Toxicol. Appl. Pharmacol., 2000, 167, 46–54.
45. Bauer, U.; Cheruvallath, Z.; Deuschle, U.; Dneprovskaia, E.; Gahman, T.; Giegrich, K.; Hanecak, R.; Hebert, N.; Kiely, J.; Kober, I.; Kogl, M.; Kranz, H.; Kremoser, C.; Lee, M.; Otte, K.; Sage, C.; Sud, M. FXR NR1H4 nuclear receptor binding compounds. PCT Int. Appl., WO2003/015771, 2003 (Lion Biosciences AG).
46. Boggs, S.D.; Collins, J.L.; Hyatt, S.M.; Maloney, P.R. Farnesoid X receptor agonists. PCT Int. Appl., WO2004/048349, 2004 (Smith- Kline Beecham Corp.).
47. Kainuma, M.; Kasuga, J.; Hosoda, S.; Wakabayashi, K.; Tanatani, A.; Nagasawa, K.; Miyachi, H.; Makishima, M.; Hashimoto, Y. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands. Bioorg. Med. Chem. Lett., 2006, 16, 3213–3218.
48. Kainuma, M.; Makishima, M.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. Bioorg. Med. Chem., 2007, 15, 2587–2600.
49. Miura, S.; Shimada, M.; Marui, S.; Tamura, N.; Nakada, Y.; Tozawa, R.; Sakamoto, J.; Funabashi, Y.; Hosono, H. Heterocyclic amide compound and use thereof. PCT Int. Appl., WO2007/052843, 2007 (Takeda Pharmaceutical Company Ltd.).
50. Deaton, D.N.; McFadyen, R.B.; Navas, F.; Caldwell, R.; Spearing, P.K. Farnesoid X receptor agonists. PCT Int. Appl., WO2007/076260, 2007 (SmithKline Beecham Corp.).
51. Bell, M.G.; Genin, M.J.; Lander, P.A.; Stelzer, L.S.; Doti, R.A.; Agejas-Chicharro, F.J.; Bueno M., Ana B.; Manninen, P.R.; Ochoada, J.M.; Shen, Q.; Warshawsky, A.M.; Ma, T.; Stites, R.E. Compounds and methods for modulating FX-receptors. PCT Int. Appl., WO2007/092751, 2007 (Eli Lilly and Company).
52. Kremoser, C.; Deuschle, U.; Abel, U.; Schulz, A. Heterocyclic FXR binding compounds. PCT Int. Appl., WO2008/025539, 2008 (Phenex Pharmaceuticals AG).
53. Kremoser, C.; Deuschle, U.; Abel, U.; Schulz, A. Heterocyclic FXR binding compounds. PCT Int. Appl., WO2008/025540, 2008 (Phenex Pharmaceuticals AG).
54. Bass, J.Y.; Deaton D.N.; Caravella, J.; McFayden, R.B.; Navas, F.; Spearing, P.K. Farnesoid X receptor agonists. PCT Int. Appl., WO2008/051942, 2008 (SmithKline Beecham Corp.).
55. Stokes, A.; Ambroso, J.; Cummings, C.; Berridge, B.; Prescott, J. A 4-Week BID oral gavage toxicity study of a farnesoid X receptor (FXR) agonist in Crl:CD(SD) rats. American College of Toxicology 29th Annual Meeting, Tucson, Arizona 2008.
56. Deaton, D.N.; Navas, F.; Spearing, P.K. Farnesoid X receptor agonists. PCT Int. Appl., WO2008/157270, 2008 (SmithKline Beecham Corp.).
57. Akwabi-Ameyaw, A.A.; Deaton, D.N.; McFadyen, R.B.; Navas, F. Farnesoid X receptor agonists. PCT Int. Appl., WO2009/005998, 2009 (SmithKline Beecham Corp.).
58. Abel, U.; Kremoser, C. Heterocyclic cyclopropyl-substituted FXR binding compounds. PCT Int. Appl., WO2009/149795, 2009 (Phenex Pharmaceuticals AG).
59. Kremoser, C.; Abel, U.; Steeneck, C.; Kinzel, O. Novel FXR (NR1H4) binding and activity modulating compounds. PCT Int. Appl., WO2011/020615, 2011 (Phenex Pharmaceuticals AG).
60. Kinzel, O.; Steeneck, C.; Kremoser, C. Novel FXR (NR1H4) binding and activity modulating compounds. PCT Int. Appl., WO2013/007387, 2013 (Phenex Pharmaceuticals AG).
61. Tully, D.C.; Rucker, P.V.; Alper, P.B.; Mutnick, D.; Chianelli, D. Compositions and methods for modulating FXR. PCT Int. Appl. WO2012/087519, 2012 (IRM LLC).
62. Tully, D.C.; Vidal, A.; Mutnick, D.; Alper, P.B. Compositions and methods for modulating farnesoid X receptors. PCT Int. Appl., WO2012/087520, 2012 (IRM LLC).
63. Tully, D.C.; Chianelli, D. Compositions and methods for modulating farnesoid X receptors. PCT Int. Appl., WO2012/087521, 2012 (IRM LLC).
64. The clogD was calculated with MarvinView from ChemAxon Ltd.
65. Protein Data Bank (http://www.rcsb.org/pdb/home/home.do) entries: 3RUT, 3RUU, 3RVF, 3HC5, 3HC6, 3P88, 3P89, 3FXV, 3DCT, 3DCU and 3GD2.
66. Mi, L.-Z.; Devarakonda, S.; Harp, J.M.; Han, Q.; Pellicciari, R.; Willson, T.M.; Khorasanizadeh, S.; Rastinejad, F. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell., 2003, 11, 1093-1100.
67. Brzozowski, A.M.; Pike, A.C.W.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G.L.; Gustafsson, J.-Å.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389, 753-758.
68. Pike, A.C.W.; Brzozowski, A.M.; Walton, J.; Hubbard, R.E.; Bonn, T.; Gustafsson, J.-Å.; Carlquist, M. Structural aspects of agonism and antagonism in the oestrogen receptor. Biochem. Soc. Trans., 2000, 28, 396-400.
69. Williams, S.; Bledsoe, R.K.; Collins, J.L.; Boggs, S.; Lambert, M.H.; Miller, A.B.; Moore, J.; McKee, D.D.; Moore, L.; Nichols, J.; Parks, D.; Watson, M.; Wisely, B.; Willson, T.M. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J. Biol. Chem., 2003, 278, 27138-27143.
70. International Transporter Consortium: Giacomini, K.M.; Huang, S.M.; Tweedie, D.J.; Benet, L.Z.; Brouwer, K.L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.M.; Hoffmaster, K.A.; Ishikawa, T.; Keppler, D.; Kim, R.B.; Lee, C.A.; Niemi, M.; Polli, J.W.; Sugiyama, Y.; Swaan, P.W.; Ware, J.A.; Wright, S.H.; Yee, S.W.; Zamek-Gliszczynski, M.J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug. Discov., 2010, 9, 215-236.
71. Hughes, J.D.; Blagg, J.; Price, D.A.; Bailey, S.; DeCrescenzo, G.A.; Devraj, R.V.; Ellsworth, E.; Fobian, Y.M.; Gibbs, M.E.; Gilles, R.W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett., 2008, 18, 4872-4875.